Abstract
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, hav......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
